Aptorum Group Limited rose 64.95% in intraday trading, following the announcement of a definitive agreement for an all-stock merger transaction with DiamiR Biosciences. The merger will see DiamiR Biosciences become a wholly-owned subsidiary of Aptorum Group, which is expected to enhance the company's capabilities in developing innovative blood-based tests for brain health and other diseases.
Comments
No comments yet